JP2017507131A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507131A5
JP2017507131A5 JP2016550573A JP2016550573A JP2017507131A5 JP 2017507131 A5 JP2017507131 A5 JP 2017507131A5 JP 2016550573 A JP2016550573 A JP 2016550573A JP 2016550573 A JP2016550573 A JP 2016550573A JP 2017507131 A5 JP2017507131 A5 JP 2017507131A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antibody agent
agent according
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016550573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507131A (ja
JP6707455B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/015510 external-priority patent/WO2015123362A1/en
Publication of JP2017507131A publication Critical patent/JP2017507131A/ja
Publication of JP2017507131A5 publication Critical patent/JP2017507131A5/ja
Application granted granted Critical
Publication of JP6707455B2 publication Critical patent/JP6707455B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016550573A 2014-02-11 2015-02-11 新規フルスペクトル抗デング抗体 Active JP6707455B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461938605P 2014-02-11 2014-02-11
US61/938,605 2014-02-11
PCT/US2015/015510 WO2015123362A1 (en) 2014-02-11 2015-02-11 Novel full spectrum anti-dengue antibody

Publications (3)

Publication Number Publication Date
JP2017507131A JP2017507131A (ja) 2017-03-16
JP2017507131A5 true JP2017507131A5 (enExample) 2018-03-22
JP6707455B2 JP6707455B2 (ja) 2020-06-10

Family

ID=53800606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550573A Active JP6707455B2 (ja) 2014-02-11 2015-02-11 新規フルスペクトル抗デング抗体

Country Status (12)

Country Link
US (3) US9902764B2 (enExample)
EP (1) EP3104888A4 (enExample)
JP (1) JP6707455B2 (enExample)
KR (1) KR20160119806A (enExample)
CN (1) CN106413749B (enExample)
AU (1) AU2015217149B2 (enExample)
BR (1) BR112016017764A2 (enExample)
CA (1) CA2938495A1 (enExample)
IL (1) IL246788A0 (enExample)
MX (1) MX375402B (enExample)
SG (2) SG10201807826XA (enExample)
WO (1) WO2015123362A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
JP6297560B2 (ja) 2012-08-07 2018-03-20 マサチューセッツ インスティテュート オブ テクノロジー 抗デングウイルス抗体およびその使用
CA2938495A1 (en) * 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
SG11201606624WA (en) 2014-02-11 2016-09-29 Visterra Inc Antibody moleules to dengue virus and uses thereof
CA2974547A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof
EP3433274A1 (en) 2016-03-25 2019-01-30 Visterra, Inc. Formulation of antibody molecules to dengue virus
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd Composition for prophylaxis or treatment of il-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2022008719A (ja) * 2016-11-23 2022-01-14 セルヴァス エーアイ インコーポレイテッド 疾患発症予測方法及び装置
EA201900326A1 (ru) 2016-12-23 2019-11-29 Усовершенствованные способы повышения продуктивности антител в культурах клеток млекопитающих и сведения к минимуму агрегации в процессах выделения и очистки, получения композиций и стабильные композиции антител, полученные этими способами
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
EP0804070B1 (en) 1993-03-09 2000-05-24 Genzyme Corporation Process of isolation of proteins from milk
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JPH07299655A (ja) 1994-04-30 1995-11-14 Aisin Seiki Co Ltd 内スプライン歯面仕上機
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
JP2006504801A (ja) 2002-11-01 2006-02-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乾燥方法
CA2548808C (en) 2003-12-08 2015-07-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
EP2257624B9 (en) 2008-02-05 2012-08-01 Medical Research Council Methods and compositions
US8858947B2 (en) * 2008-10-05 2014-10-14 The Board Of Trustees Of The Leland Stanford Junior University Hepatitis C antibodies and uses thereof
CN102272155B (zh) * 2008-10-13 2018-05-25 生物医学研究所 登革热病毒中和抗体及其用途
KR20110097923A (ko) 2008-12-05 2011-08-31 엘파스, 인크. 항-지질 항체 결정 구조를 이용한 항체 설계
WO2010093335A1 (en) 2009-02-10 2010-08-19 Nanyang Technological University Antibodies for diagnosis and treatment of flaviviral infections
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US8637035B2 (en) 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
WO2013089647A1 (en) 2011-12-16 2013-06-20 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
WO2013173348A1 (en) * 2012-05-14 2013-11-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Cross-reactive antibodies against dengue virus and uses thereof
JP6297560B2 (ja) 2012-08-07 2018-03-20 マサチューセッツ インスティテュート オブ テクノロジー 抗デングウイルス抗体およびその使用
CA2938495A1 (en) * 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
SG11201606624WA (en) * 2014-02-11 2016-09-29 Visterra Inc Antibody moleules to dengue virus and uses thereof

Similar Documents

Publication Publication Date Title
JP2017507131A5 (enExample)
JP2020522261A5 (enExample)
JP2016529882A5 (enExample)
JP2017535257A5 (enExample)
JP2017501711A5 (enExample)
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2015503909A5 (enExample)
JP2015525795A5 (enExample)
JP2011509245A5 (enExample)
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
JP2018502060A5 (enExample)
IL261666B1 (en) Binding proteins and methods of use thereof
JP2018508188A5 (enExample)
JP2010536384A5 (enExample)
JP2017505121A5 (enExample)
JP2014534806A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
RU2018129874A (ru) Антитела против фактора свертывания xi
JP2019505527A5 (enExample)
JP2021500916A5 (enExample)
JP2005528914A5 (enExample)
JP2017537082A5 (enExample)
US12173081B2 (en) CD19/CD38 multispecific antibodies
JP2013508292A5 (enExample)
JP2016501877A5 (enExample)